Vitamin D and Parkinson's Disease
Parkinson's disease patients have among the highest rates of vitamin D deficiency in any chronic disease cohort (50–70%). The substantia nigra — where PD's dopaminergic neurodegeneration is centred — has the highest density of vitamin D receptors in the brain, providing a biological rationale for a role in the disease.
Deficiency prevalence
Sato 1997 reported severely low 25(OH)D in Japanese PD patients. Subsequent studies from Europe, North America, and Asia confirm rates of 25(OH)D < 20 ng/mL in 50–70% of PD patients — significantly higher than age-matched controls. Reduced sun exposure from mobility limitation and cognitive changes contributes, but the disparity persists after adjustment.
Supplementation trials
- Suzuki 2013 — 114 PD patients (Japan); 1,200 IU/day for 12 months significantly slowed UPDRS progression vs placebo, particularly in patients with the FokI VDR polymorphism.
- Habibi 2017 — 51 PD patients; 50,000 IU biweekly × 8 weeks: significant reduction in UPDRS-III (motor) subscale.
- Cohort follow-ups — sufficient 25(OH)D associated with slower motor progression and cognitive decline.
- Larger definitive trials still lacking.
Falls prevention in PD
Falls are a major cause of morbidity in PD — postural instability, freezing of gait, and orthostatic hypotension all contribute. Vitamin D + muscle strength/ balance training reduces falls in older adults generally, and by extension in PD patients. Correcting deficiency is standard care independent of disease- modifying speculation.
Practical guide
- Test 25(OH)D at PD diagnosis and annually.
- Correct deficiency: 2,000–4,000 IU/day cholecalciferol.
- Combine with structured balance / gait training and physical therapy.
- DEXA and osteoporosis workup — PD patients have elevated fracture risk.
- Vitamin D is adjunctive to standard PD therapy (levodopa, dopamine agonists, MAO-B inhibitors, DBS in appropriate patients).